[Question] how do you actually verify 503B
how do you actually verify 503B. If this has been answered properly somewhere, link me and I will delete.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
salt forms are the recurring argument and the answer is boring
shortage status changes and the whole arrangement changes with it
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Added a jurisdiction tag — the answers to this question are completely different in different countries.
What did the intake actually ask you?
a telehealth intake that asks nothing has told you what it is
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
the pharmacy and the prescriber are two separate questions
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.